Jiudian Pharmaceuticals: Jiu Dian Z02 is expected to trigger downward revision conditions for the conversion price.

Jiudian Pharmaceutical announced that from May 14th to 27th, 2026, the closing price of the company's stock has been lower than 85% of the conversion price of Jiudian Z02 for ten consecutive trading days, triggering the possibility of downward revision of the conversion price. If further triggers occur, the board of directors has the authority to decide whether to propose a revision plan and submit it to the shareholders' meeting for a vote. On the day of the trigger, the board of directors will convene to review whether to make a revision and disclose it promptly. Investors should pay attention to subsequent announcements and investment risks.